News und Analysen
![VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR): https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005694/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
![Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality
Regulatory News:
Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron
![VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005914/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
![Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency
Regulatory News:
Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress. Simultaneously, results
![Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201108005065/en/
Vifor Pharma and Angion Biomedica Corp. (Angion)
![VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005955/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
![BB Biotech: Ein drittes Quartal zum Abhaken](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
BB Biotech: Ein drittes Quartal zum Abhaken
BB Biotech (WKN: A0NFN3) legte heute seinen Quartalsbericht vor und informierte zugleich über „erhöhte Übernahmeaktivitäten“ im Pharmasektor, aus denen die Investmentgesellschaft selbst Kapital
![Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005725/en/
Vifor Pharma and Cara Therapeutics, Inc
![Vifor Pharma announces outcome of AFFIRM-AHF topline data: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Vifor Pharma announces outcome of AFFIRM-AHF topline data
Regulatory News:
Vifor Pharma today announced topline data from its AFFIRM-AHF study evaluating the effect of Ferinject® (intravenous ferric carboxymaltose) on heart failure hospitalizations and
![Vifor Pharma Group Announces Successful Sale of OM Pharma](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Vifor Pharma Group Announces Successful Sale of OM Pharma
Regulatory News:
Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal
![Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee
Regulatory News:
Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020.
![Vifor Pharma Group Reports Continued Growth in H1 2020](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Vifor Pharma Group Reports Continued Growth in H1 2020
Regulatory News:
Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic. The financial guidance has been updated to reflect
![Vifor Pharma Gruppe wächst auch im 1. Halbjahr 2020 weiter](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Vifor Pharma Gruppe wächst auch im 1. Halbjahr 2020 weiter
Regulatory News:
Die Vifor Pharma Gruppe ist trotz der Herausforderungen, die Patienten auch während der COVID-19-Pandemie zu erreichen, im 1. Halbjahr 2020 weiter gewachsen. Die Finanzprognose
![VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005052/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
![92. Generalversammlung der Vifor Pharma Gruppe](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
92. Generalversammlung der Vifor Pharma Gruppe
Regulatory News:
An der 92. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Beschlussanträge des Verwaltungsrats genehmigt.
Aufgrund der aktuellen Situation und im
![92nd Vifor Pharma Group Annual General Meeting](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
92nd Vifor Pharma Group Annual General Meeting
Regulatory News:
At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.
In view of the current situation
![Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients
Regulatory News:
Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes
![BB Biotech: So geht Rendite mit COVID-19-Aktien!](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
BB Biotech: So geht Rendite mit COVID-19-Aktien!
Interessante Einblicke in den Geschäftsverlauf im Auftaktquartal liefert heute BB Biotech (WKN: A0NFN3). Die mussten zwar Rückschläge einstecken, glänzten aber auch durch Überraschungen – die mit
![VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200420005949/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
![Update on 92nd Vifor Pharma Ltd. Annual General Meeting](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Update on 92nd Vifor Pharma Ltd. Annual General Meeting
Regulatory News:
Vifor Pharma confirmed that it will hold its Annual General Meeting (AGM) on 14 May, 2020, as planned. In view of the current situation and based on Art. 6a of Ordinance 2
![Update zur 92. Generalversammlung der Vifor Pharma AG](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Update zur 92. Generalversammlung der Vifor Pharma AG
Regulatory News:
Vifor Pharma hat bestätigt, dass die Generalversammlung des Unternehmens wie geplant am 14. Mai 2020 abgehalten wird. Aufgrund der aktuellen Situation und im Einklang mit Art. 6a
![Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
Regulatory News:
Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The
![Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose
Regulatory News:
Die Vifor Pharma Gruppe erzielte 2019 ein starkes finanzielles und operatives Ergebnis dank Fokus auf die drei strategischen Wachstumstreiber und gezielten Investitionen in die
![Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings
Regulatory News:
Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This investment
![Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio
Vifor Pharma today announced a strategic partnership with Fresenius Kabi to create a new joint company based in the People’s Republic of China expanding its access to the second largest